文献速递膀胱癌与上尿路尿路上皮癌

RESECT试验:非肌层浸润性膀胱癌手术中审计与反馈的随机对照研究

RESECT: A Randomised Controlled Trial of Audit and Feedback in Non-muscle-invasive Bladder Cancer Surgery.
PubMed 文献 · Eur Urol · 2025-12-24

干预组显著改善肿瘤特征记录和切除完整性记录,但单次灌注化疗、逼尿肌取样和早期复发率无显著差异。

要点

  • 审计反馈联合教育可改善肿瘤特征和切除完整性的记录。
  • 对单次灌注化疗、逼尿肌取样和早期复发率无显著影响。
  • 对照组早期复发率较基线下降,可能稀释干预效果。

核心结论

  • 审计反馈联合教育改善了影响临床管理的重要手术发现记录,但未改善逼尿肌取样、辅助化疗使用或早期复发率。

研究设计与样本

  • 干预为审计反馈联合同行比较与教育,对照为单纯审计,比较四个共同主要结局和早期复发率。

主要发现

  • 干预组肿瘤特征记录显著改善,校正均值差6.0(95%CI 1.8–10),p=0.005。
  • 干预组切除完整性记录显著改善,校正均值差5.5(95%CI 1.5–9.5),p=0.007。
  • 化疗使用无显著差异,校正均值差0.3(95%CI -4.7–5.3),p=0.9。
  • 逼尿肌取样无显著差异,校正均值差2.6(95%CI -1.3–6.4),p=0.2。
  • 早期复发率组间无显著差异,校正比值比1.02(95%CI 0.8–1.4),p=0.9;对照组早期复发率较基线下降,校正比值比0.7(95%CI 0.6–0.9)。

关键数值与推荐

  • 共同主要结局包括单次灌注化疗、逼尿肌取样、肿瘤特征记录和切除完整性。
  • 早期复发为次要结局。

临床怎么用

  • 审计反馈联合教育可用于改善非肌层浸润性膀胱癌手术中肿瘤特征和切除完整性的记录质量。
  • 对逼尿肌取样、辅助化疗使用和早期复发率的改善有限,需结合其他干预措施。

局限性

  • 对照组早期复发率较基线下降,可能解释部分结局缺乏干预效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: We aimed to determine whether audit, feedback, and education improves surgical performance after transurethral resection of bladder tumour surgery for non-muscle-invasive bladder cancer and as a secondary aim if it reduced recurrence rates. METHODS: This cluster randomised controlled trial compared audit and feedback plus peer comparison and education, with audit alone for four coprimary outcomes: (1) Single-instillation chemotherapy, (2) detrusor muscle sampling, (3) documentation of tumour features, and (4) resection completeness. Early recurrence was a secondary outcome. KEY FINDINGS AND LIMITATIONS: A total of 100 sites were randomised to intervention and 101 to control. In total, 14 915 patients were included. Intervention sites significantly improved documentation of tumour features (adjusted mean difference [95% confidence interval {CI}]: 6.0 [1.8, 10], p = 0.005) and of resection completeness (adjusted mean difference [95% CI]: 5.5 [1.5, 9.5], p = 0.007). There was no statistically significant difference in chemotherapy use (adjusted mean difference [95% CI]: 0.3 [-4.7, 5.3], p = 0.9) or detrusor muscle sampling (adjusted mean difference [95% CI]: 2.6 [-1.3, 6.4], p = 0.2). There was no statistically significant difference in early recurrence rate between arms (adjusted odds ratio [95% CI]: 1.02 [0.8, 1.4], p = 0.9); however, in the control arm, the early recurrence rate reduced compared with baseline (adjusted odds ratio [95% CI]: 0.7 [0.6, 0.9]). CONCLUSIONS AND CLINICAL IMPLICATIONS: Audit and feedback with education improved the documentation of important surgical findings that influence clinical management, but not the performance of detrusor muscle sampling, adjuvant chemotherapy use, or early recurrence rates. Improvements observed in the control arm may explain a lack of effect of the intervention in some outcomes.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Gallagher K, MacLennan S, Bhatt N, et al. RESECT: A Randomised Controlled Trial of Audit and Feedback in Non-muscle-invasive Bladder Cancer Surgery. Eur Urol. 2025. PMID: 41444076. doi:10.1016/j.eururo.2025.09.4174

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。